Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Non Small Cell Lung Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02040870
What this trial is testing

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Ended earlyNCT04211922
What this trial is testing

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 4
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Testing effectiveness (Phase 2)Study completedNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Early research (Phase 1)Active Not RecruitingNCT02393625
What this trial is testing

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
ALK-positive NSCLC
Novartis Pharmaceuticals 57
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Testing effectiveness (Phase 2)Active Not RecruitingNCT05015010
What this trial is testing

Alectinib in Neo-adjuvant Treatment of Stage III NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Gruppo Oncologico Italiano di Ricerca Clinica 33
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06779539
What this trial is testing

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
West China Hospital 33
Early research (Phase 1)UnknownNCT02695550
What this trial is testing

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Centaurus Biopharma Co., Ltd. 40
Large-scale testing (Phase 3)Active Not RecruitingNCT06082635
What this trial is testing

TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non Small Cell Lung Cancer
Shenzhen TargetRx Co., Ltd. 321
Not applicableEnrolling By InvitationNCT07122882
What this trial is testing

Integrated Genomics in Oncogene-driven NSCLC With Acquired Resistance

Who this might be right for
Oncogene-addicted Non Small Cell Lung CancerEGFR MutationALK Fusion-positive Solid or CNS Tumors+10 more
Chang Gung Memorial Hospital 40
Large-scale testing (Phase 3)Study completedNCT02604342
What this trial is testing

Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Hoffmann-La Roche 119
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06780839
What this trial is testing

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

Who this might be right for
NSCLC, Stage I, II, IIIA, IIIB
Peking University Cancer Hospital & Institute 70
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Testing effectiveness (Phase 2)UnknownNCT04415320
What this trial is testing

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

Who this might be right for
Lung Cancer, Nonsmall CellBrain Metastases
Betta Pharmaceuticals Co., Ltd. 37
Not applicableLooking for participantsNCT06487078
What this trial is testing

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Who this might be right for
ALK+ Non-Small-Cell Lung Carcinoma
Pfizer 90
Next Page